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osting by EAbstract A simple and sensitive kinetic method was described for the determination of hyoscine
butylbromide in pharmaceutical preparations. The method is based upon a kinetic investigation
of the oxidation reaction of the drug with alkaline potassium permanganate at room temperature
for a ﬁxed time of 15 min. The absorbance of the colored manganate ion was measured at
610 nm. The absorbance–concentration plot was rectilinear over the range of 1.0–10 lg mL1
(r= 0.9999) and detection limit of 0.092 lg mL1. The concentration of hyoscine butylbromide
was calculated using the corresponding calibration equation for the ﬁxed-time method. The deter-
mination of hyoscine butylbromide by the ﬁxed-concentration and rate constant methods is also
feasible with the calibration equations obtained but the ﬁxed-time method has been found to be
more applicable. The different experimental parameters affecting the development and stability of
the colors were carefully studied and optimized. The proposed method was applied to the deter-
mination of hyoscine butylbromide in pharmaceutical formulations. The results obtained were in
good agreement with those obtained using the ofﬁcial British Pharmacopeial method (2004).
ª 2009 King Saud University. All rights reserved.om
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lsevier1. Introduction
Hyoscine butylbromide (HBB) (1S,3s, 5R, 7S,8r)-6,7-
epoxy-3-[(S)-(3-hydroxy-2-phenylpropiony)oxy]-8-butyl-8-
methyl-8-azoniabicyclol [3.2.1] octane bromide is used as an
antispasmodic in treating peptic ulcer, gastritis and various
disorders of the gastrointestinal tract which are characterized
by spam. It has also found employment for the relief of spas-
modic conditions of the bile duct and urinary tract and for the
treatment of dysmenorrhoea (Crossland, 1980) (Fig. 1).
Hyoscine butylbromide is a white, crystalline powder or
colorless crystals, efﬂorescent, freely soluble in water, solu-
ble in alcohol. It melts at about 197 C with decomposition,
OH
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Figure 1 Chemical structure of hyoscine butylbromide (HBB).
34 A.A. Goudadetermined after drying in vacuo for 24 h and then at 100–
105 C for 2 h and it should be protected from light (Neil
Maryadele, 2001; British pharmacopoeia, 2004).
Due to the vital importance of HBB determination in
pharmaceutical preparations and in biological ﬂuids, many
analytical techniques have been reported in the literature.
HBB has been determined in pharmaceutical preparations
using titrimetric (British pharmacopoeia, 2004; Falco and
Vianna, 1979), spectrophotometric (Taha and Gomaa, 1975;
Taha et al., 1974; Taha and Ruecker, 1997; Abdelkader
et al., 1980; Issa et al., 2005; Thomos et al., 1994; Davidson
and Hassan, 1984; Mahrous et al., 1992; Sharaf El-Din, 1994;
Erk and Onur, 1996; Erk, 1996; Abramovich et al., 1993;
Issopoulos and Pavlouzervou, 1994; Toral et al., 2005), high
performance liquid chromatographic (Karali et al., 1998;
Huller et al., 1993; Nakagawa et al., 2000; Wang and Zhu,
2000; Mandal et al., 1991; Pohjola and Harpf, 1994; Issopo-
ulos and Pavlouzervou, 1994; Lau and Mok, 1997; Parissi-
poulou and Panderi, 1999), capillary electrophoresis (Cherka-
oui et al., 1999; Chang et al., 2000) and electrochemical meth-
ods (Abadia et al., 1982; Ionescu et al., 1983; Cheng and
Gao, 1983; Buschmann, 1987; Li et al., 1988; Ganjali et al.,
2003, 2004), among other methods.
The literatures are still poor in analytical procedures based
on kinetics especially for pharmaceutical or biological ﬂuids.
Furthermore, some speciﬁc advantages in the application of
kinetic methods can be expected (Espinosa-Mansilla et al.,
1998):
1. Selectivity due to the measurement of the evolution
of the absorbance with the time of reaction instead
of the measure of a concrete absorbance value.
2. Possibility of no interference of the colored and: or
turbidity background of the samples.
3. Possibility of no interference of other active com-
pounds present in the commercial product if they
are resisting the chemical reaction conditions estab-
lished for the proposed kinetic method.
In the present work, kinetically based method was proposed
for the determination of HBB by measuring the absorbance at
610 nm after oxidation reaction with alkaline KMnO4.
Although, the poor selectivity of the proposed oxidation meth-
od with KMnO4, it is simpler than the time consuming HPLC
methods and is more sensitive than the other spectrophotomet-
ric methods.The aim of the present work was to study the reaction
between HBB and potassium permanganate kinetically in
an attempt to evaluate the drug in dosage forms. The re-
sults obtained were promising. The proposed method was
simple and did not need sophisticated instrument or special
skill.
2. Experimental
2.1. Apparatus
All absorption spectra were made using Kontron 930 (UV–
Visible) spectrophotometer (German) with a scanning speed
of 200 nm/min and a band width of 2.0 nm, equipped with
10 mm matched quartz cells.
2.2. Materials and reagents
All chemicals and materials were of analytical grade and all
solutions were freshly prepared in bidistilled water.
Pure grade hyoscine butylbromide (HBB) was kindly sup-
plied by Amriya Pharmaceutical Industries, Alexandria,
Egypt. Its purity was found to be 100.28 ± 0.77 (n= 5)
according to BP method (British pharmacopoeia, 2004).
The following commercial formulations were subjected to
the analytical procedures: Nu-Spasm tablets (Egyptian Inter-
national Pharmaceutical Industries Company (EIPICO),
Tenth of Ramadan City, Egypt) labeled to contain 10 mg
HBB/tablet. Farcorelaxin ampoules (Pharco Pharmaceuticals
Company, Al Amriya, Alexandria, Egypt) labeled to contain
20 mg HBB/mL. Spasmocin ampoules (Memphis Company
for Pharmaceutics and Chemistry, Cairo, Egypt) labeled to
contain 20 mg HBB/mL.
A stock solution (100 lg mL1) was prepared by dissolving
10 mg of HBB in 100 mL of distilled water and further diluted
with the same solvent as appropriate.
Potassium permanganate (Merck, Darmstadt, Germany):
5 · 103 M aqueous solutions, freshly prepared and stan-
dardized. Sodium hydroxide (BDH, UK): 0.5 M aqueous
solution.
2.3. Recommended general procedures
Transfer aliquots (0.1–1.0 mL) of 100 lg mL1 standard solu-
tion accurately measured, into series of 10 mL volumetric
ﬂasks; add 1.0 mL of 0.5 M NaOH followed by 2.0 mL of
5 · 103 M KMnO4 to each ﬂask and shake the mixture well.
Allow the reaction mixture to stand for 15 min. Make up to
the volume with bidistilled water. The HBB concentration
was determined by measuring the rate of manganate formation
at 610 nm as the tangent of the kinetic curve during the ﬁrst
3.0 min of reaction and using the appropriate graphs. Log
reaction rate versus log concentration of HBB was plotted to
get order of the reaction. To get the standard calibration
graph, the above procedure was carried out and the reaction
mixture was allowed to stand for 15 min, where the absorbance
of the reacting solution was measured at 610 nm against a
blank solution prepared simultaneously. Plot the values of
the absorbance against the ﬁnal concentration in lg mL1 to
get the calibration graph. Alternatively, derive the regression
equation.
Kinetic spectrophotometric determination of hyoscine butylbromide 352.4. Procedures for pharmaceutical formulations
2.4.1. For tablets
Thoroughly powder and mix the contents of 10 tablets of the
investigated drug and accurately weigh, an amount of the pow-
der equivalent to 10 mg of HBB. Shake well with warm water
for 5.0 min and complete to 100 mL with bidistilled water in a
measuring ﬂask. Filter if necessary and further dilute with
water as required. The general procedure described above
was used for the determination of the drug concentration using
the corresponding regression equation.
2.4.2. For ampoules
The content of ﬁve ampoules was mixed and diluted to 100 mL
with bidistilled water. An accurately measured volume equiva-
lent to 10 mg of HBB was further diluted with water in a
100 mL volumetric ﬂask to obtain a test solution of proper
concentration. The general procedure described above was
used for the determination of the drug concentration using
the corresponding regression equation.
3. Results and discussion
3.1. Kinetic and optimization of the reaction conditions
The reaction between HBB and KMnO4 in alkaline medium
yields a green color due to the production of manganate ion,
which absorbs at 610 nm (Fig. 2). As the intensity of the color
increases with time, this was used as a useful method for the
determination of HBB in pharmaceutical formulations.
The spectrophotometric properties of the colored product
as well as the different experimental parameters affecting the
color development and its stability were carefully studied
and optimized. Such factors were changed individually while
the others were kept constant. These factors include, effect0
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Figure 2 Absorption spectra of the reaction product of HBB
after reaction with KMnO4/NaOH system. (A) Reaction product
8.0 lg mL1 against reagent blank (1 · 104 M KMnO4) (B).of temperature, concentration of the reagents (KMnO4 and
NaOH), different solvents, and time.
3.2. Effect of temperature
At room temperature, the reaction rate increased substantially
as the color development increased. Therefore, room tempera-
ture was selected as the optimum temperature. Heating the
solution was found to increase the rate of the reaction but
MnO2 was precipitated.
3.3. Effect of KMnO4
The reaction rate and maximum absorbance increased with
time, and with increasing KMnO4 concentration. It was found
that 2.0 ± 0.1 mL of 5 · 103 M KMnO4 was adequate for the
maximum absorbance (Fig. 3).
3.4. Effect of NaOH
The inﬂuence of NaOH concentration on the reaction rate was
also studied using 0.2–3.0 mL of 0.5 M NaOH. It was found
that increasing the volume of 0.5 M NaOH would increase
the absorbance of the reaction product up to 1.0 mL, after
which further increase in the volume of 0.5 M NaOH resulted
in a very slight decrease in the absorbance of the reaction prod-
uct, thus, 1.0 mL of 0.5 M NaOH was found to be the most
suitable concentration for maximum absorbance (Fig. 4).
3.5. Effect of solvent
The effect of diluting solvent was also studied. Different sol-
vents such as bidistilled water, ethanol, acetonitrile and di-
methyl sulfoxide were used. It was found that bidistilled
water was the best solvent as it gave the highest absorbance
reading.
The rate of reaction was also found to be dependent on
HBB concentrations. The rates were followed at room temper-
ature with various concentrations of HBB in the range of 1.0–
10 lg mL1 keeping KMnO4 and NaOH concentrations
constant.
The reaction rate was found to obey the following equation:
rate ¼ K0  ½HBBn; ð1Þ
where K0 is the pseudo-order rate constant and n is the order of
the reaction.0
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Figure 3 Effect of 5 · 103 M KMnO4 volume on the absor-
bance of HBB (8.0 lg mL1) at 610 nm.
Table 2 Values of K0 calculated from slopes of log A versus t
graphs at 610 nm.
K0 · 104 [HBB]
5.34 4.542 · 106
4.52 9.08 · 106
3.81 1.36 · 105
2.76 1.82 · 105
1.89 2.271 · 105
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Figure 5 Absorbance versus time graphs for the reaction
between HBB and MnO4 =OH
 system showing the dependence
of the reaction on HBB concentrations. Concentrations of HBB
are: (1) 2.271 · 106; (2) 4.542 · 106; (3) 9.08 · 106; (4)
1.36 · 105; (5) 1.82 · 105; (6) 2.271 · 105 M.
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Figure 4 Effect of 0.5 M NaOH volume on the absorbance of
HBB (8.0 lg mL1) at 610 nm.
Table 1 Logarithms of rates for different concentrations of
HBB at room temperature at 610 nm.
log DA/Dt log [HBB] M
4.151 5.644
3.824 5.343
3.538 5.042
3.337 4.86
3.229 4.741
3.125 4.644
log DA/Dt= 0.9807 log C  1.5799, R2 = 0.9995.
36 A.A. GoudaThe rate of the reaction may be estimated by the variable-
time method measurement (Weisberger et al., 1953) as
DA/Dt, where A is the absorbance and t is the time in seconds.
Taking logarithms of rates and concentrations (Table 1), Eq.
(1) is transformed into:
logðrateÞ ¼ logDA=Dt ¼ log k0 þ n log½HBB: ð2Þ
At 610 nm; regression of log (rate) versus log (HBB) gave the
regression equation:
log rate ¼ logDA=Dt ¼ 1:5799þ 0:9807 logC ðr ¼ 0:9995Þ:
Hence K0 = 2.63 · 102 s1 and the reaction is ﬁrst order
(n= 0.9807).
3.6. Evaluation of the kinetic methods
The quantitation of HBB under the optimized experimental
conditions outlined above would result in a pseudo-ﬁrst order
with respect to their concentrations where KMnO4 concentra-
tion was at least 20 times of the concentration of HBB and
NaOH concentration was at least 250 times the initial concen-
tration of HBB.
Several experiments were then carried out to obtain HBB
concentration from the rate data according to Eq. (1). Initial
rate, rate constant, ﬁxed-concentration and ﬁxed-time methods
(Yatsimirskii, 1966; Laitinen and Harris, 1975) were tried and
the most suitable analytical method was selected taking into
account the applicability, the sensitivity, the intercept and
the correlation coefﬁcient (r).3.7. Rate-constant method
Graphs of log absorbance versus time for HBB concentration
in the range of 4.452 · 106 to 2.271 · 105 M were plotted
and all appeared to be rectilinear. Pseudo-ﬁrst order rate con-
stants (K0) corresponding to different HBB concentrations (C)
were calculated from the slopes multiplied by 2.303 and are
presented in Table 2. Regression of C versus K0 gave the
equation:
K0 ¼ 5:9051 104 þ 19:049C ðr ¼ 0:9991Þ:3.8. Fixed-concentration method
Reaction rates were recorded for different HBB concentrations
in the range of 9.08 · 106 to 2.271 · 105 M. A preselected
value of the absorbance (0.4) was ﬁxed and the time was mea-
sured in seconds and the reciprocal of time (1/t) varies in the
range 7.937 · 104 to 2.87 · 103 S1. The reciprocal of time
(1/t) versus the initial concentration of HBB was plotted and
the following equation of the calibration graph was obtained:
1=t ¼ 6:004 104 þ 150:87C ðr ¼ 0:9985Þ:3.9. Fixed-time method
Reaction rates were determined for different concentrations of
HBB. At a preselected ﬁxed-time, which was accurately deter-
mined, the absorbance was measured. Calibration graphs of
absorbance versus initial concentration of HBB were estab-
Table 3 Regression equation for HBB at different ﬁxed time
over the range 2.271 · 106 to 2.271 · 105 M at room
temperature at 610 nm.
Time (min) Regression equation Correlation coeﬃcient (r)
3 A= 0.0247 + 0.0283C 0.9988
6 A= 0.0567 + 0.0358C 0.9992
9 A= 0.0556 + 0.0491C 0.9995
12 A= 0.0714 + 0.0608C 0.9995
15 A= 0.0015 + 0.0795C 0.9999
A is the absorbance at 610 nm and C is the concentration in
lg mL1.
Kinetic spectrophotometric determination of hyoscine butylbromide 37lished at ﬁxed times of 3, 6, 9, 12, 15 min (Fig. 5) with the
regression equations assembled in Table 3.
It is clear that the slope increases with time and the most
acceptable values of the correlation coefﬁcient (r) and theTable 4 Application of the proposed method to the determination
Dosage form Taken (lg/mL)
Nu-Spasm tablets (10 mg HBB/tablet) 2
6
10
Mean ± SD
Variance
RSD
tb
Fb
Spasmocin ampoules (20 mg HBB/mL) 2
6
10
Mean ± SD
Variance
RSD
tb
Farcorelaxin ampoules (20 mg HBB/mL) 2
6
10
Mean ± SD
Variance
RSD
tb
Fb
a The results are the average of six separate determinations.
b The theoretical t- and F-values (2.365) and (6.59), respectively for ﬁv
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Figure 6 Limiting logarithmic plots for the molar ratio:intercept were obtained for a ﬁxed time of 15 min, which was
therefore chosen as the most suitable time interval for
measurement.
After optimizing the reaction conditions, the ﬁxed-time
method was applied to the determination of HBB in pure form
over the concentration range 1.0–10 lg mL1 and molar
absorptivity 3.472 · 104 l mol C m1. Analysis of the data gave
the following regression equations:
A ¼ 0:0015þ 0:0795C ðr ¼ 0:9999Þ;
where A is the absorbance at 610 nm.
The LOD was found to be 0.092 lg mL1 (2.09 · 107 M)
and LOQ was found to be 0.3036 lg mL1 (6.90 · 107 M).
Statistical analysis (Miller and Miller, 1993) of the results
obtained by the proposed and ofﬁcial BP method (depending
on HPLC with UV detection at 210 nm) (British pharmaco-
poeia, 2004), using Student’s t-test (0.635) and variance ratio
F-test (1.786) at P= 0.05 (the tabulated values of t (2.571)
and F (6.256) revealed no signiﬁcant difference between theof HBB in dosage forms.
Found (lg/mL) Recoverya (%)
Proposed method Oﬃcial method
1.998 99.92
6.004 100.07
9.976 99.76
99.92 ± 0.155 99.70 ± 0.16
0.024 0.0256
0.155 0.16
2.30
1.067
2.022 101.11
5.992 99.86
9.974 99.74
100.24 ± 0.759 99.89 ± 0.61
0.438 0.372
0.7569 0.611
0.847
2.005 100.25
5.994 99.90
9.982 99.82
99.99 ± 0.229 99.80 ± 0.15
0.0523 0.0225
0.2287 0.15
1.65
2.324
e degree of freedom at 95% conﬁdence level.
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(A) log A vs. log [Drug]; (B) log A vs. log [KMnO4].
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Figure 7 The proposed mechanism of reaction between HBB and KMnO4/NaOH.
38 A.A. Goudaperformance of the two methods regarding the accuracy and
precision).
The precision of the method was evaluated by analyzing
standard solutions of HBB. The results for pure sample were
in accordance with those obtained by the BP method (British
pharmacopoeia, 2004). The method was also applied to tablets
or ampoules containing HBB (Table 4). The results agreed
with those obtained by the BP method (British pharmaco-
poeia, 2004).
Excipients such as talc, starch, gelatin, magnesium stearate
and lactose did not interfere with the assay.
3.10. Mechanism of the reaction
The stoichiometry of the reaction was studied adopting Bent
and French method (1941). The absorbance of the reaction
product was alternatively measured in the presence of excess
of either KMnO4 or HBB. A plot of log absorbance versus
log [KMnO4] and log [HBB] gave straight lines; the values of
the slopes are 0.7962 and 0.3996, respectively (Fig. 6). Hence,
it is concluded that, the molar reactivity of the reaction is
0.7962/0.3996, i.e. the reaction proceeds in the ratio of 2:1.
Based on the obtained molar reactivity, the proposed mecha-
nism of reaction between HBB and KMnO4 in alkaline med-
ium is shown in Fig. 7.
4. Conclusion
Different kinetic methods were established to determine HBB,
where, the reaction rate, rate constant and ﬁxed-time methods
were applied over the concentration range 5.4 · 106 to
5.4 · 105 M HBB. The ﬁxed-concentration method was ap-
plied over the range 2.70 · 105 to 5.4 · 105 M. Applying
ﬁxed-time method, it was clear that the slope increased with
time and the most acceptable values of correlation coefﬁcient
(r) and intercept were obtained for a ﬁxed time of 15 min
which was therefore chosen as the most suitable time interval
for measurements.
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